Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Jul 15, 2025; 17(7): 106723
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.106723
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.106723
Table 3 Clinical trials of chimeric antigen receptor-T cell therapy for colorectal cancer
| Antigen | NCT number | Sponsor | Phases | Start date | Completion date |
| CEA | NCT04513431 | Ruijin Hospital | EARLY_PHASE1 | August 30, 2020 | August 30, 2023 |
| NCT02349724 | Southwest Hospital, China | PHASE1 | December 1, 2014 | December 1, 2019 | |
| NCT02959151 | Shanghai GeneChem Co., Ltd. | PHASE1|PHASE2 | July 1, 2016 | July 1, 2018 | |
| NCT05396300 | Fang WJ, MD | PHASE1 | May 25, 2022 | May 15, 2025 | |
| NCT05736731 | A2 Biotherapeutics Inc. | PHASE1|PHASE2 | April 28, 2023 | December 1, 2028 | |
| NCT05240950 | Changhai Hospital | PHASE1 | August 25, 2022 | December 25, 2025 | |
| NCT06043466 | Chongqing Precision Biotech Co., Ltd | PHASE1 | August 11, 2023 | December 31, 2027 | |
| NCT03682744 | Sorrento Therapeutics, Inc. | PHASE1 | September 13, 2018 | March 1, 2021 | |
| NCT02850536 | Roger Williams Medical Center | PHASE1 | February 1, 2017 | September 17, 2021 | |
| GUCY2C | NCT06718738 | Beijing Immunochina Medical Science and Technology Co., Ltd. | PHASE1 | December 15, 2024 | August 15, 2026 |
| NCT06675513 | Wondercel Biotech (ShenZhen) | EARLY_PHASE1 | November 10, 2024 | December 30, 2029 | |
| NCT05319314 | Innovative Cellular Therapeutics Inc. | PHASE1 | August 1, 2022 | October 1, 2024 | |
| MSLN | NCT05089266 | Shanghai Cell Therapy Group Co., Ltd | PHASE1 | November 30, 2021 | January 30, 2025 |
| NCT06051695 | A2 Biotherapeutics Inc. | PHASE1|PHASE2 | April 3, 2024 | June 1, 2029 | |
| NCT06256055 | UTC Therapeutics Inc. | PHASE1 | March 5, 2024 | April 1, 2025 | |
| NKG2DL | NCT05248048 | The Third Affiliated Hospital of Guangzhou Medical University | EARLY_PHASE1 | September 13, 2021 | October 1, 2022 |
| NCT04550663 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | PHASE1 | September 25, 2020 | March 25, 2023 | |
| NCT04107142 | CytoMed Therapeutics Pte Ltd | PHASE1 | December 1, 2019 | March 1, 2021 | |
| NCT04991948 | Celyad Oncology | PHASE1 | November 22, 2021 | May 25, 2038 | |
| MUC1 | NCT02617134 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | PHASE1|PHASE2 | November 1, 2015 | November 1, 2018 |
| NCT05239143 | Poseida Therapeutics, Inc. | PHASE1 | February 15, 2022 | April 1, 2039 | |
| CDH17 | NCT06055439 | Chimeric Therapeutics | PHASE1|PHASE2 | May 15, 2024 | May 1, 2027 |
| C-met | NCT03638206 | Shenzhen BinDeBio Ltd. | PHASE1|PHASE2 | March 1, 2018 | March 1, 2023 |
| EGFR | NCT06682793 | A2 Biotherapeutics Inc. | PHASE1|PHASE2 | March 31, 2025 | March 31, 2030 |
| EpCAM | NCT05028933 | Zhejiang University | PHASE1 | September 30, 2021 | December 31, 2024 |
| HER2 | NCT02713984 | Yang Z | PHASE1|PHASE2 | March 1, 2016 | July 1, 2019 |
| NCT03740256 | Baylor College of Medicine | PHASE1 | December 14, 2020 | December 30, 2038 | |
| CD133 | NCT02541370 | Chinese PLA General Hospital | PHASE1|PHASE2 | June 1, 2015 | June 1, 2019 |
| LGR5 | NCT05759728 | Carina Biotech Limited | PHASE1|PHASE2 | October 24, 2023 | December 1, 2027 |
| B7-H3 | NCT05190185 | PersonGen BioTherapeutics (Suzhou, Jiangsu Province) Co., Ltd. | PHASE1 | June 1, 2021 | December 1, 2023 |
- Citation: Chen MY, Wang C, Wang YG, Shi M. Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells. World J Gastrointest Oncol 2025; 17(7): 106723
- URL: https://www.wjgnet.com/1948-5204/full/v17/i7/106723.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i7.106723